Drug intelligence / Profile preview

EN2001

Development stage: Preclinical
Lead developer: Enosi Life Sciences
Modality: Small Molecules

Overview

EN2001 is a preclinical TNF-inhibiting molecule developed by Enosi Life Sciences for the treatment of inflammatory diseases, particularly rheumatoid arthritis. It functions by trapping inflammatory EGF-like growth factors, thereby preventing tissue destruction through inhibition of the growth of cells that form pannus, the destructive tissue in arthritic joints. This offers a novel approach distinct from traditional TNF inhibitors by targeting downstream inflammatory pathways.

Other names: EN2001EN-2001EN 2001

Beyond the preview

Go deeper on EN2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EN2001.

Explore the full profile